A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX?23 One Year Later in Healthy Adults 50 Years of Age or Older (PN

Project: Other project

StatusActive
Effective start/end date6/11/186/10/20

Funding

  • Merck Sharp & Dohme Corporation: $54,231.27